Stifel analyst Thomas Stephan maintains $Glaukos (GKOS.US)$ with a buy rating, and maintains the target price at $145.
According to TipRanks data, the analyst has a success rate of 54.8% and a total average return of 12.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:
Glaukos' Q3 results surpassed consensus estimates, supported by an $8.8M contribution from iDose. Moreover, the company experienced a 12.3% growth in its iStent infinite and the broader iStent portfolio within the U.S. market. Additionally, the Glaucoma business has been expanding steadily at a rate of over 20% internationally.
Glaukos' third-quarter sales outperformed consensus expectations, bolstered by iDose and OUS MIGS, leading to an upward revision of sales guidance by approximately $5 million at the midpoint, equivalent to the scale of the outperformance. The momentum for iDose is expected to continue positively into the fourth quarter and towards 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Thomas Stephan維持$Glaukos (GKOS.US)$買入評級，維持目標價145美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.8%，總平均回報率為12.5%。
此外，綜合報道，$Glaukos (GKOS.US)$近期主要分析師觀點如下：
在iDose的880萬美元捐款的支持下，Glaukos第三季度的業績超過了共識預期。此外，該公司的iStent Infinite和美國市場上更廣泛的iStent投資組合增長了12.3％。此外，青光眼業務一直在穩步增長，國際增長率超過20％。
在iDose和OUS MIGS的推動下，Glaukos第三季度的銷售表現超出市場普遍預期，導致銷售預期在中點上調了約500萬美元，相當於跑贏大盤的規模。預計iDose的勢頭將持續到第四季度和2025年。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
